Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 396

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Multitarget Therapy for Induction Treatment of Lupus Nephritis: A Randomized Trial

Liu, Zhihong, Zhang, Haitao, Liu, Zhangsuo, Xing, Changying, Fu, Ping, Ni, Zhaohui, Chen, Jianghua, Lin, Hongli, Liu, Fuyou, He, Yongcheng, He, Yani, Miao, Lining, Chen, Nan, Li, Ying, Gu, Yong, Shi, Wei, Hu, Weixin, Liu, Zhengzhao, Bao, Hao, Zeng, Caihong, Zhou, Minlin·2015·Annals of Internal Medicine

Abstract

BACKGROUND: Treatment of lupus nephritis (LN) remains challenging. OBJECTIVE: To assess the efficacy and safety of a multitarget therapy consisting of tacrolimus, mycophenolate mofetil, and steroid compared with intravenous cyclophosphamide and steroid as induction therapy for LN. DESIGN: 24-week randomized, open-label, multicenter study. (ClinicalTrials.gov: NCT00876616). SETTING: 26 renal centers in China. PATIENTS: Adults (aged 18 to 65 years) with biopsy-proven LN. INTERVENTION: Tacrolimus, 4 mg/d, and mycophenolate mofetil, 1.0 g/d, versus intravenous cyclophosphamide with a starting dose of 0.75 (adjusted to 0.5 to 1.0) g/m2 of body surface area every 4 weeks for 6 months. Both groups received 3 days of pulse methylprednisolone followed by a tapering course of oral prednisone therapy. MEASUREMENTS: The primary end point was complete remission at 24 weeks. Secondary end points included overall response (complete and partial remission), time to overall response, and adverse events. RESULTS: After 24 weeks of therapy, more patients in the multitarget group (45.9%) than in the intravenous cyclophosphamide group (25.6%) showed complete remission (difference, 20.3 percentage points [95% CI, 10.0 to 30.6 percentage points]; P < 0.001). The overall response incidence was higher in the multitarget group than in the intravenous cyclophosphamide group (83.5% vs. 63.0%; difference, 20.4 percentage points [CI, 10.3 to 30.6 percentage points]; P < 0.001), and the median time to overall response was shorter in the multitarget group (difference, -4.1 weeks [CI, -7.9 to -2.1 weeks]). Incidence of adverse events did not differ between the multitarget and intravenous cyclophosphamide groups (50.3% [91 of 181] vs. 52.5% [95 of 181]). LIMITATION: The study was limited to 24 weeks of follow-up. CONCLUSION: Multitarget therapy provides superior efficacy compared with intravenous cyclophosphamide as induction therapy for LN. PRIMARY FUNDING SOURCE: National Basic Research Program of China, National Key Technology R&D Program.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.7326/m14-1030

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 396

Metadata

Authors
Liu, Z., Zhang, H., Liu, Z., Xing, C., Fu, P., Ni, Z., Chen, J., Lin, H., Liu, F., He, Y., He, Y., Miao, L., Chen, N., Li, Y., Gu, Y., Shi, W., Hu, W., Liu, Z., Bao, H., Zeng, C., & Zhou, M.
Venue
Annals of Internal Medicine
Published
2015-01-06
Volume
162
Issue
1
Pages
18-26
ISSN
  • 0003-4819 (ISSN-L)
  • 1539-3704
OpenAlex
W2073246129
Cited by
396
References
1
FWCI
21.02
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Multitarget Therapy for Induction Treatment of Lupus Nephritis: A Randomized Trial. https://app.cochat.ai/papers/10.7326/m14-1030
The paper
Liu, Z., Zhang, H., Liu, Z., Xing, C., Fu, P., Ni, Z., Chen, J., Lin, H., Liu, F., He, Y., He, Y., Miao, L., Chen, N., Li, Y., Gu, Y., Shi, W., Hu, W., Liu, Z., Bao, H., . . . Zhou, M. (2015). Multitarget Therapy for Induction Treatment of Lupus Nephritis: A Randomized Trial. Annals of Internal Medicine. https://doi.org/10.7326/m14-1030

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.